This prospective study aims to observe the predictive effect of peripheral blood plasma biomarker on the outcome of treatment in children with different types of amblyopia. We also investigated the mechanism of neuromodulation in the visual development of amblyopic children.
Study Type
OBSERVATIONAL
Enrollment
600
amblyopia treatment following international guidelines and genetic tests.
Zhongshan Ophthalmic Center
Guangzhou, Guangdong, China
RECRUITINGPlasma protein predictor screening for visual acuity improvement following amblyopia therapy using Tandem Mass Tags proteomics
Peripheral blood will be collected prior and after treatment. The plasma will be separated and Tandem Mass Tags will be used for proteomics. We will detect the different expression of plasma protein between successfully treated and untreated amblyopia patients to find biomarkers that predict amblyopia treatment success. Amblyopia treatment success is defined as best corrected visual acuity (BCVA) improvement of 3 or more logMAR lines.
Time frame: 2 years after including into this clinical trial
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.